This is an old revision of this page, as edited by Beetstra (talk | contribs) at 12:34, 25 February 2011 (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: ChEMBL.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 12:34, 25 February 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: ChEMBL.)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H20N2 |
| Molar mass | 216.33 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
N-Methyl-N-isopropyltryptamine (MIPT) is a psychedelic tryptamine, closely related to DMT, DIPT and Miprocin.
Chemistry
MIPT base, unlike many other tryptamines in their freebase form, does not decompose rapidly in the presence of light in oxygen.
Dosage
10-25 mg is usually taken orally, with effects lasting 4-6 hours.
Effects
MIPT is said to emphasize psychedelic/entheogenic effects over sensory/hallucinogenic activity. Users report strong mental effects, but few perceptual alterations.
Legality
MiPT is unscheduled in the United States.